亿胜生物科技(01061.HK)签知识产权特许协议 涉资逾1,200万元
亿胜生物科技(01061.HK)公布,旗下全资附属与特许人订立知识产权特许协议,根据知识产权特许协议,特许人於评估期内向受许人授出有限、不可转让、不可撤销的於领域内使用领域的独家许可,以使用评估材料评估於领域内使用领域开发及商业化分子的适用性。公司向特许人支付总额不超过155万美元(相当於约1,201.3万港元)的费用。
特许人广州康睿生物医药科技主要从事眼科药物及治疗方法开发业务,为公司独立第三方。集团在肿瘤科领域的策略发展计划,董事认为,知识产权特许协议为集团评估分子在肿瘤治疗用途及治疗方法领域的研发及商业化的适用性提供了良机。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.